CIK 0000014272
- Large accelerated filer
BRISTOL MYERS SQUIBB CO
Sign in to watch- Ticker
- BMY
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 220790350
- Phone
- +1 609-252-4621
- Business address
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
Securities
- BMY Bristol-Myers Squibb Company Common Stock NYSE
- CELG-RI Rights NYSE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $677,826
- in 3 filings
Net −$677,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-10 | von Autenried Paul EVP, Chief Information Officer | Grant or award · Market Share Units | +9,287 | 9,287 | ||
| 2021-03-10 | von Autenried Paul EVP, Chief Information Officer | Exercise or conversion · Performance Shares | −11,502 | 0 | ||
| 2021-03-10 | von Autenried Paul EVP, Chief Information Officer | Grant or award · Performance Shares | +13,930 | 13,930 | ||
| 2021-03-01 | Elkins David V EVP, Chief Financial Officer | Exercise or conversion | +24,579 | 91,759 | ||
| 2021-03-01 | Elkins David V EVP, Chief Financial Officer | Shares withheld for taxes | −8,573 | $61.63 | $528K | 83,186 |
| 2021-03-01 | Elkins David V EVP, Chief Financial Officer | Exercise or conversion · Restricted Stock Units | +24,579 | 24,577 | ||
| 2021-03-01 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +23,349 | 80,572 | ||
| 2021-03-01 | VESSEY RUPERT EVP, Research & Early Dev. | Shares withheld for taxes | −8,944 | $61.63 | $551K | 71,628 |
| 2021-03-01 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Restricted Stock Units | +23,349 | 23,350 | ||
| 2021-02-04 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +3,592 | 58,409 | ||
| 2021-02-04 | VESSEY RUPERT EVP, Research & Early Dev. | Shares withheld for taxes | −1,186 | $61.56 | $73K | 57,223 |
| 2021-02-04 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Restricted Stock Units | −3,592 | 3,593 | ||
| 2021-02-01 | Price Paula A Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 4,535.41 |
| 2021-02-01 | SATO VICKI L Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 75,689.43 |
| 2021-02-01 | YALE PHYLLIS R Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 9,009.78 |
| 2021-02-01 | Vousden Karen H Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 17,779.1 |
| 2021-02-01 | BERTOLINI ROBERT J Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 26,094.07 |
| 2021-02-01 | Arduini Peter J Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 31,537.42 |
| 2021-02-01 | Haller Julia A Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 9,174.75 |
| 2021-02-01 | Emmens Matthew Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 26,424.7 |
Page 84 of 90 · 1,795 trades